The aim of this study was to calculate the costs of the current initial treatment of acute myeloid leukemia. Resource use was collected for 202 patients who started with intensive chemotherapy in 2008 or 2009. The costs of the first induction course were significantly higher than the costs of the second induction course. Allogeneic transplantation from a matched unrelated donor was significantly more expensive than the other consolidation treatments. In-hospital stay was the major cost driver in the treatment of AML. Research regarding possibilities of achieving the same or better health outcome with lower costs is warranted.

, , , , ,,
Leukemia Research: clinical and laboratory studies
Erasmus School of Health Policy & Management (ESHPM)

van Dongen-Leunis, A., Blommestein, H., Huijgens, P., Blijlevens, N., Jongen-Lavrencic, M., & Uyl-de Groot, C. (2013). The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leukemia Research: clinical and laboratory studies, 37(3), 245–250. doi:10.1016/j.leukres.2012.09.018